nerandomilast » Trang Công Nghệ | Trangcongnghe.vn

CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU

Globe Newswire

CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU

Globenewswire -

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

Globe Newswire

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

Globenewswire -

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults

Globe Newswire

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults

Globenewswire -

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

Globe Newswire

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

Globenewswire -

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)

Globe Newswire

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)

Globenewswire -

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Globe Newswire

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Globenewswire -

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

Globe Newswire

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

Globenewswire -

XEM THÊM TIN MỚI